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In the well-fed state a relatively high activity of the pyruvate dehydrogenase complex (PDC) reduces blood glucose levels by di-
recting the carbon of pyruvate into the citric acid cycle. In the fasted state a relatively low activity of the PDC helps maintain blood 
glucose levels by conserving pyruvate and other three carbon compounds for gluconeogenesis. The relative activities of the pyru-
vate dehydrogenase kinases (PDKs) and the opposing pyruvate dehydrogenase phosphatases determine the activity of PDC in 
the fed and fasted states. Up regulation of PDK4 is largely responsible for inactivation of PDC in the fasted state. PDK4 knockout 
mice have lower fasting blood glucose levels than wild type mice, proving that up regulation of PDK4 is important for normal 
glucose homeostasis. In type 2 diabetes, up regulation of PDK4 also inactivates PDC, which promotes gluconeogenesis and there-
by contributes to the hyperglycemia characteristic of this disease. When fed a high fat diet, wild type mice develop fasting hyper-
glycemia but PDK4 knockout mice remain euglycemic, proving that up regulation of PDK4 contributes to hyperglycemia in diabe-
tes. These finding suggest PDK4 inhibitors might prove useful in the treatment of type 2 diabetes. 
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REGULATION OF PYRUVATE 
DEHYDROGENASE COMPLEX
In the well-fed state the pyruvate dehydrogenase complex (PDC) 
is converted into its most active dephosphorylated state in or-
der to direct pyruvate into the citric acid cycle. PDC activity is 
tightly regulated by phosphorylation by four pyruvate dehy-
drogenase kinases (PDKs) and dephosphorylation by two py-
ruvate dehydrogenase phosphatases (PDPs) (Fig. 1) [1,2]. The 
PDKs and PDPs exhibit unique tissue expression patterns, ki-
netic properties, and sensitivities to regulatory molecules [3,4]. 
All four PDKs are subject to regulation at the level of transcrip-
tion. Expression of PDK1 and PDK3 is stimulated by HIF1α [5-
7], making these PDKs of considerable interest in hypoxia and 
cancer. Expression of PDK2 and PDK4 is controlled by nutri-
tional factors and hormones [8-16], making their roles of great 
interest in starvation and diabetes. PDK3 has received less atten-
tion, but is emerging as important since its expression is subject 
to regulation by HIF1α [7] and the carbohydrate response ele-
ment binding protein (ChREBP) [17]. Although the PDKs are 
encoded by genes located in the nucleus, they are markedly 
different in sequence and three-dimensional structure from 
other serine protein kinases present in eukaryotic cells, which 
may facilitate the discovery of specific small molecule inhibi-
tors. Phosphorylation of serine residues of the E1α component 
of PDC by PDKs inactivates the complex (Fig. 1). Dephosphor-
ylation by PDPs activates the complex. The complex does not 
exist in any tissue in a completely active, dephosphorylated state 
Review
doi: 10.4093/kdj.2010.34.5.274
pISSN 1976-9180 · eISSN 2093-2650275
Role of PDK4 in glucose metabolism
Korean Diabetes J 2010;34:274-283 www.e-kdj.org
nor in a completely inactive, phosphorylated state. The relative 
activities of the PDKs and the opposing PDPs determine the 
extent of phosphorylation and therefore the activity of the com-
plex. Induced changes in activities of the kinases relative to the 
phosphatases during transitions to different nutritional and 
hormonal states result in substantial change in the phosphory-
lation state and therefore PDC activity. The products of the 
overall reaction, acetyl-CoA and NADH, indirectly inhibit the 
complex by activating the PDKs [18]. A high [NADH]/[NAD
+] 
ratio caused by fatty acid oxidation reduces the lipoyl moieties 
of E2. A high [acetyl-CoA]/[CoA] ratio caused by fatty acid 
oxidation promotes acetylation of the reduced lipoyl moieties 
of E2. Binding of PDK to an E2 lipoyl domain in which the li-
poyl group is reduced and acetylated results in maximum kinase 
activity (Fig. 1) [19]. The consequence is greater E1 phosphory-
lation and less PDC activity. Whereas the products of PDC pro-
mote inactivation of the complex, its substrates (pyruvate, NAD
+, 
and CoA) induce activation by inhibition of the kinases (Fig. 1) 
[20]. Pyruvate is most important since its concentration fluc-
tuates more dramatically in different nutritional states. Since 
PDK4 is less sensitive to pyruvate inhibition than PDK2, the 
shift to greater PDK4 expression during fasting and fat feeding 
decreases the effectiveness of pyruvate as an activator of PDC 
in these nutritional states [21].
  During fasting PDC is progressively shut down by phosphor-
ylation in most tissues of the body. High serum levels of free 
fatty acids (FFAs) generated by lipolysis in the adipose tissue 
promote fatty acid oxidation in most tissues of the body. Re-
duced insulin levels and elevated levels of serum FFAs and glu-
cocorticoids induce expression of PDK4 in muscle, kidney, liv-
er, and heart, and PDK2 in liver and kidney. Inhibition of the 
conversion of pyruvate to acetyl-CoA by decreased PDC activ-
ity induced by the PDKs in peripheral tissues, especially skele-
tal muscle, heart, and liver, conserves three carbon compounds 
(pyruvate, lactate, and alanine) that are used by the liver to make 
glucose. Inactivation of the PDC in the liver blocks ketone body 
synthesis from three carbon compounds but allows ketone 
body synthesis from fatty acids and ketogenic amino acids. In-
hibition of ketogenesis from three carbon compounds is criti-
cal because no pathway exists for the conversion of ketone bod-
ies into glucose. Conservation of the compounds that can be 
used to synthesize glucose at the expense of compounds that 
can not be converted to glucose (fatty acids, acetyl-CoA, and 
ketone bodies) helps maintain the blood glucose levels required 
by the brain and red blood cells. Inactivation of the PDC in 
starvation indirectly conserves body protein because it mini-
mizes the need for gluconeogenesis from gluconeogenic ami-
no acids and prevents complete oxidation of the carbon skele-
tons of gluconeogenic amino acids. Indeed, survival during 
long-term starvation depends upon inactivation of PDC. If the 
complex remained active in the starved state, the three carbon 
compounds needed for gluconeogenesis would be converted to 
CO2 in peripheral tissues and to ketone bodies in the liver. Since 
survival requires maintenance of glucose levels, animals would 
have to consume their protein stores at a faster rate as a carbon 
source for the gluconeogenesis. Since pyruvate is an interme-
diate in the catabolism of several amino acids, much of the car-
bon coming from protein would be wasted. Thus, control of 
the PDC plays an important role in determining the fuel used 
by tissues in different nutritional and hormonal states.
IMPORTANCE OF REGULATION OF PDC BY 
PDK IN TYPE 2 DIABETES
 
Remarkable upregulation of PDK4 occurs in humans with type 
2 diabetes [13,22,23], in genetic animal models of type 2 diabe-
tes [24], in animals fed a high fat diet [21], and in humans fed 
a high fat diet [25]. Type 2 diabetes is usually the result of a com-
bination of insulin resistance and insulin insufficiency. In the 
insulin resistance state, the pancreas still makes insulin but the 
amount released is not enough to normalize blood glucose. 
Would a PDK inhibitor prove useful in the treatment of type 2 
diabetes? Perhaps, but it is not certain. Boosting PDC activity 
in tissues with a PDK inhibitor will lower blood glucose levels 
which may reduce the toxic effects of hyperglycemia on the 
Fig. 1.  Regulation of the pyruvate dehydrogenase complex 
(PDC) and its kinases (PDKs) and phosphatases (PDPs). 
DCA, dichloroacetate.
DCA
Lipoic acid Fatty acids and 
glucocorticoids
Hif-1a
PDC
PDC
ADP
ATP
OH 
P
H2O
 Ca
2+
Pi
Active
Inactive
PDK1
PDK2
PDK3
PDK4
PDP1
PDP2
CoA-SH
Pyruvate
NAD
+
CO
2
Acetyl-CoA
NADH
Insulin
Insulin
Starvation and 
diabetes276
Jeoung NH, et al.
Korean Diabetes J 2010;34:274-283 www.e-kdj.org
beta cells of the pancreas. However, if the prevailing hypothe-
sis for the mechanism responsible for insulin resistance is cor-
rect (Fig. 2) [26], greater PDC activity might exacerbate insu-
lin resistance. Elevated levels of FFAs are associated with in-
flammation and insulin resistance. A defect in mitochondrial 
fatty acid oxidation may be responsible. The combination of 
uptake of too much unesterified fatty acid in the face of re-
duced or defective fatty acid oxidation results in the accumu-
lation of TAG as well as proinflammatory lipids (fatty acyl-
CoA, diacylglycerol, and ceramide) that activate the serine/thre-
onine stress kinases (JNK, IKKβ, and PKCθ) that are responsible 
for inactivation of components of the insulin signaling cascade 
[27]. PDK4 deficiency increases blood levels of FFAs and in-
hibits fatty acid oxidation [28], a combination that would be 
expected to induce insulin resistance by this mechanism. As to 
how PDK4 deficiency inhibits fatty acid oxidation, greater PDC 
activity may lead to an increase in malonyl-CoA, inhibitor of 
carnitine palmitoyltransferase I (CPT1), the rate-limiting en-
zyme in fatty acid oxidation. Since long chain acyl-CoA esters 
are converted to carnitine esters by CPT1, inhibition of CPT1 
by malonyl-CoA should increase long chain acyl-CoA esters 
which in turn may increase diacylglycerol and ceramide, result-
ing in insulin resistance. It is known that inhibition acetyl-CoA 
carboxylase which produces malonyl-CoA protects against diet-
induced insulin resistance [29]. In spite of what on paper seems 
should happen, PDK4 deficiency partially protects mice against 
diet-induced insulin resistance [29]. Although this finding 
doesn’t fit with the model giving in Fig. 2, there are other find-
ings that challenge the current view of the mechanism by which 
fatty acids induce insulin resistance. For example, data obtained 
with malonyl-CoA decarboxylase knockout mice also do not 
support this model [30]. Theoretically, elevated levels of malo-
nyl-CoA in the malonyl-CoA decarboxylase knockout mouse 
should inhibit CPT1 and thereby increase long chain acyl-CoA 
esters, diacylglycerol, and ceramide, which in turn should in-
duce insulin resistance by activation of the stress kinases. In-
stead, malonyl-CoA decarboxylase knockout mice are partial-
ly protected, like PDK4
-/- mice, against the development of in-
sulin resistance. Based on these findings, Koves et al. [30] pro-
posed that high levels of FFAs may induce a mitochondrial 
overload or stress by exceeding the capacity of the mitochon-
dria for fatty acid oxidation. They further proposed that mito-
chondrial overload may induce the accumulation of “incom-
plete products of fatty acid oxidation,” e.g., acyl carnitine ester 
intermediates that function as proinflammatory compounds re-
sponsible for activation of the stress kinases. 
ARE THE PDKs VIABLE TARGETS FOR THE 
TREATMENT OF TYPE 2 DIABETES?
Upregulation of PDK4 in diabetes begs the question of whether 
PDK4 and the other PDKs should be considered therapeutic 
targets for the treatment of diabetes. PDK4
-/- mice, generated 
in an attempt to answer this question, have lower than normal 
fasting blood glucose levels and slightly but significantly better 
glucose tolerance [28]. This is observed in both chow-fed 
PDK4
-/- mice that have normal insulin sensitivity [28] and di-
et-induced obese PDK4
-/- mice that are insulin resistant [31]. 
Dichloroacetate, a well-established PDK inhibitor, decreases 
fasting blood glucose levels but has relatively low potency and 
long term treatment causes peripheral neuropathy [32-34]. 
2-chloroproprionate also inhibits the PDKs, lowers fasting 
blood glucose levels, but also induces peripheral neuropathy 
[35]. α-Lipoic acid also inhibits the PDKs [36], stimulates py-
ruvate oxidation and inhibits fatty acid oxidation and gluco-
neogenesis by hepatocytes [37]. These effects likely explain 
why lipoic acid increases insulin-stimulated glucose disposal in 
patients with type 2 diabetes [38] and decreases blood levels of 
lactate and pyruvate [39]. Nevertheless, the mechanism of ac-
tion of lipoic acid is complicated by its conversion to a CoA es-
ter which inhibits mitochondrial processes by sequestering 
Fig. 2.  Current model for mechanism responsible for insulin 
resistance. FFA, free fatty acid; DAG, diacylglycerol; MCD, 
malonyl-CoA decarboxylase; ACC, acetyl-CoA carboxylase; 
TAG, triacylglycerol. 
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CoA in the mitochondrial matrix space [40]. The latter inhibits 
gluconeogenesis [41] and may increase the concentration of 
AMP and thereby stimulate AMP-activated protein kinase [41]. 
A synthetic inhibitor of the PDKs, SDZ048-619, increases PDC 
activity in tissues of the hyperglycemic Zucker diabetic rat and 
reduces blood lactate but, surprisingly, does not lower blood 
glucose [42]. In contrast, AZD7545, originally reported to be a 
specific inhibitor of PDK2 [43], but which we now know also 
inhibits PDK1 and PDK3 [44], markedly lowers blood glucose 
in hyperglycemic Zucker diabetic fatty rats [45]. Leelamine, 
another synthetic inhibitor of the PDKs [46] looks particularly 
promising as a lead compound. It lowers blood glucose in ob/
ob mice [46], and inhibits glyceroneogenesis in isolated adipo-
cytes by activating PDC [47]. 
ROLE OF GLYCERONEOGENESIS IN 
ACCUMULATION OF FAT IN TISSUES
 
The term glyceroneogenesis refers to a pathway for the synthe-
sis of the glycerol moiety of TAG from precursors other than 
glucose (Fig. 3) [48]. The pathway of glyceroneogenesis from 
lactate, pyruvate, and alanine shares many steps with gluconeo-
genesis from these substrates. Indeed, like gluconeogenesis, 
glyceroneogenesis is of greater importance in the fasted state 
than in the well-fed state. Dietary fat, absorbed as chylomicrons, 
is cleared from the circulation by adipose tissue lipoprotein lipase 
which releases FFAs. FFAs are esterified with glycerol 3-phos-
phate derived from glycolysis (using glucose taken up via in-
sulin-stimulated GLUT4). During fasting, low insulin levels 
permit the activation of TAG lipases by protein kinase A, hy-
drolysis of stored TAG, and release of FFAs and glycerol. Much 
of this FFA is recycled within adipose tissue by re-esterifica-
tion with glycerol 3-phosphate. Since insulin levels are low, 
glucose is not available for synthesis of glycerol 3-phosphate. 
Glycerol 3-phosphate therefore must be generated either by 
“glyceroneogenesis” from pyruvate, lactate, or alanine, or by 
phosphorylation of glycerol by glycerol kinase. Glyceroneo-
genesis is quantitatively much more important than the for-
mer [48]. Indeed, like gluconeogenesis, glyceroneogenesis de-
pends on the activity of cytosolic phosphenolpyruvate car-
boxykinase (PEPCK), which converts oxaloacetate to phos-
phoenolpyruvate (PEP). Knocking out PEPCK expression in 
white adipose tissue abolishes glyceroneogenesis from pyru-
vate [49], resulting in lipodystrophic mice. Conversely, over ex-
pression of PEPCK in white adipose tissue increases the rate of 
glyceroneogenesis from pyruvate, resulting in obese mice [50]. 
Likewise, over-expression of PEPCK in skeletal muscle results in 
massive fat accumulation in muscles [51]. Thus, the pathway of 
glyceroneogenesis plays an important role in intracellular fat 
accumulation. Although not directly on the pathway of glycer-
oneogenesis, PDC is positioned to interfere with glyceroneo-
genesis by the same mechanism that it interferes with gluco-
neogenesis, i.e., by reducing the availability of lactate, pyru-
vate, and alanine (Fig. 3). Furthermore, glyceroneogenesis has 
also been shown to be the most important source of glycerol 
3-phosphate for the synthesis of VLDL in the human liver 
[52]. It is estimated that glucose via glycolysis provides ~15% 
of glycerol 3-phosphate required for TAG synthesis whereas 
direct phosphorylation of free glycerol provides ~35% and 
glyceroneogenesis provides ~50%. Therefore, our working hy-
pothesis is that abolishment of PDK activity can reduce adi-
posity (and therefore body weight) by limiting the availability 
of lactate, pyruvate, and alanine for glyceroneogenesis in adi-
pose, liver, and other tissues. Indeed, activation of PDC by in-
hibition of PDK inhibits glyceroneogenesis in isolated adipo-
cytes [47]. 
KNOCKING OUT PDK4 REDUCES GLUCOSE 
LEVELS IN FASTING AND STARVATION
Strong upregulation of PDK4 during fasting and starvation 
suggests a dominant role for this PDK in regulation of fuel ho-
meostasis in these conditions. Studies with PDK4
-/- mice sup-
port this conclusion [28,31,53]. Blood glucose levels are invari-
ably lower in overnight-fasted PDK4
-/- mice than overnight-
Fig. 3.  Pathway of glyceroneogenesis from three carbon com-
pounds. FFAs, free fatty acids; OAA, oxaloacetate; PEP, phos-
phoenolpyruvate.
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fasted wild type mice. Serum concentrations of lactate, pyru-
vate, and alanine are also always lower in PDK4
-/- mice, consis-
tent with either a faster rate of oxidation by PDC or a reduced 
rate of production of these compounds. In contrast, higher se-
rum concentrations of FFAs, acetoacetate, β-hydroxybutyrate, 
and TAG are induced by starvation in PDK4
-/- mice relative to 
wild-type mice. Branched-chain amino acids (BCAAs) are also 
higher in the blood in starved PDK4
-/- mice, consistent with 
lower blood alanine levels and the importance of BCAAs as a 
source of amino groups for alanine formation. 
  Liver glycogen levels are the same in wild-type and PDK4
-/- 
mice in the fed state but are lost more rapidly from the liver of 
PDK4
-/- mice during fasting. Concentrations of glucose and 
intermediates of the gluconeogenesis pathway are likewise 
lower (glucose 6-phosphate, fructose 1,6-bisphosphate, pyru-
vate, lactate, and citrate) or not different (dihydroxyacetone 
phosphate, glyceraldehyde 3-phosphate, phosphoenolpyruvate) 
compared to that of wild-type mice. Ketone bodies are elevated 
in concentration but with a decrease in the β-hydroxybutyrate 
to acetoacetate ratio. 
  Glucose oxidation rate, measured by 
14CO2 production from 
[U-
14C]glucose, was greater in diaphragms from PDK4
-/- mice 
relative to diaphragms from wild-type mice. Rates of lactate 
release and net glycolysis, measured by 
3H2O production from 
[5-
3H]glucose, are significantly reduced. Rates of fatty acid oxi-
dation, measured either by 
14CO2 production or acid-soluble 
product formation from [
14C]-Palmitate, are lower in dia-
phragms obtained from PDK4
-/- mice than in diaphragms from 
wild-type mice. Starvation markedly decreases actual PDC ac-
tivities in wild-type mice without significantly affecting total 
PDC activity, thereby decreasing the activity states of PDC to 
values typical of those induced in tissues of starved rats. A sig-
nificantly higher PDC activity state is observed in tissues of 
PDK4
-/- mice, consistent with a major role for PDK4 in control 
of the activity of PDC. 
KNOCKING OUT PDK2 HAS NO EFFECT ON 
BLOOD GLUCOSE LEVELS
PDK2
-/- mice have also been produced to examine the physio-
logical role of PDK2 in glucose homeostasis (N. H. Jeoung and 
R. A. Harris, unpublished). They are viable with normal 
growth characteristics on mouse chow diet. Surprisingly, blood 
glucose levels are not different from wild-type mice in the fast-
ed state. No difference in glucose levels are observed during the 
glucose tolerance test relative to age matched wild-type mice. 
Insulin sensitivity test likewise reveals no difference. PDK2
-/-
mice maintain normal PDC activities in major tissues and 
normal blood glucose levels during fasting, perhaps because 
upregulation of PDK4 compensates for lack of PDK2. 
KNOCKING OUT PDK4 LOWERS FASTING 
BLOOD GLUCOSE LEVELS, IMPROVES 
GLUCOSE TOLERANCE, AND IMPROVES 
INSULIN SENSITIVITY IN MICE FED A HIGH 
UNSATURATED-FAT, HIGH-GLUCOSE DIET
Experiments to determine the effects of knocking out PDK4 
on diabetes were carried out with mice fed a high-unsaturated 
fat, high sucrose diet that is known to induce hyperglycemia 
and insulin resistance [31]. No differences in blood metabo-
lites were found wild-type and PDK4
-/- mice maintained on 
this diet were compared in the fed state. Significant differences 
emerged, however, when blood obtained from overnight fast-
ed mice was analyzed [31]. Fasting blood glucose levels were 
significantly lower in the PDK4
-/- mice throughout an 18-week 
feeding period. PDK4
-/- mice were significantly more glucose 
tolerant than wild-type mice after 16 weeks on the high-fat diet. 
Insulin levels increased slightly in both groups during the test 
without significant differences. Nevertheless, insulin tolerance 
tests revealed significantly greater insulin sensitivity in the 
PDK4
-/- mice after 17 weeks on the diet. Glucose levels were 
20% lower in the blood of PDK4
-/- mice at the time of their 
sacrifice after 18 weeks on the high-fat diet. Gluconeogenic 
precursors (lactate, pyruvate, and alanine) were lower in the 
PDK4
-/- mice but FFAs, TAGs, 3-hydroxybutyrate, acetoacetate, 
and BCAAs were higher. 
  Total PDC activities (completely dephosphorylated state) did 
not differ between PDK4
-/- mice and wild-type mice regardless 
of whether fed or fasted. The activity states of PDC were signifi-
cantly higher in the fed state in skeletal muscle and diaphragm 
of PDK4
-/- mice. Relative to the fed state, the activity state of 
PDC was reduced by overnight fasting in all tissues of PDK4
-/- 
mice with the exception of the kidney. Likewise, in the fasted 
state the activity state of PDC was significantly higher in the 
tissues of PDK4
-/- mice. 
  Diaphragms from PDK4
-/- mice oxidize glucose at a rate 
greater than diaphragms from wild-type mice. Less pyruvate 
accumulates in the incubation medium with diaphragms from 
PDK4
-/- mice. Palmitate inhibited glucose oxidation in dia-279
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phragms from wild-type mice but exerts no inhibition with 
diaphragms from PDK4
-/- mice, indicating inhibition of glu-
cose oxidation by palmitate requires induction of PDK4. The 
rate of palmitate oxidation is lower in diaphragms isolated from 
PDK4
-/- mice relative to diaphragms from wild-type mice. 
KNOCKING OUT PDK4 REDUCES 
ADIPOSITY AND HEPATIC STEATOSIS IN 
MICE FED A HIGH-SATURATED FAT DIET
 
The experiment described above with high unsaturated-fat, 
high-sucrose fed mice was followed by studies in which wild-
type and PDK4
-/- mice were fed a high-saturated fat diet (no 
sucrose) [53] that induce high blood glucose levels, insulin re-
sistance, and (in contrast to high unsaturated-fat, high-sucrose 
diet) hepatic steatosis [54]. Wild-type and PDK4
-/- mice were 
maintained on this diet for 28 weeks. Fasting blood glucose 
levels were lower, glucose tolerance improved, and insulin sen-
sitivity greater in the PDK4
-/- mice [53]. The activity state (% 
active) of the PDC was significantly greater in liver and skele-
tal muscle of PDK4
-/- mice after overnight fasting. Serum FFAs 
and ketone bodies were elevated more in PDK4
-/- mice, consis-
tent with slower rates of oxidation. Interestingly, PDK4
-/- mice 
gained less weight than wild-type mice on the diet. Although 
the two types of mice gained similar amounts of weight for the 
first 8 weeks on the diet, the wild-type mice gained weight at a 
faster rate after this point, even though no difference in food 
consumption could be detected between the two groups. Fur-
thermore, adiposity, as measured by weight of the adipose tis-
sue relative to the body weight, was found to be 13% less in 
PDK4
-/- mice after 28 weeks on the diet. In addition, macrove-
sicular accumulation of fat was apparent in the livers of wild-
type mice by oil red O staining. Livers of PDK4
-/- mice also ex-
hibited hepatic steatosis but the fat was microvesicular and less 
than the amount present in the liver of wild-type mice [53]. 
KNOCKING OUT PDK4 INCREASES HEPATIC 
EXPRESSION OF PGC-1α 
Hepatic steatosis occurs when the amount of fat delivered to the 
liver or synthesized de novo exceeds the capacity of the liver to 
oxidize or secrete. Inhibition of fatty acid oxidation by a mito-
chondrial poison induces hepatic steatosis. Decreased expres-
sion of nuclear-encoded mitochondrial genes is believed respon-
sible for lipid accumulation in skeletal muscle in type 2 diabetes. 
Reduced mitochondrial capacity for fatty acid oxidation may 
also be responsible for hepatic steatosis in rodents fed a high 
saturated-fat diet [55]. PGC-1α, transcription coactivator for 
several nuclear transcription factors, is a key regulator of mi-
tochondrial biogenesis [56]. Disruption of the PGC-1α gene 
reduces expression of mitochondrial enzymes, reduces the num-
ber of mitochondria, and induces hepatic steatosis [57]. Con-
versely, activation of PGC-1α by over expression of SIRT1 pro-
tects the liver from the accumulation of fat in mice fed a high 
fat diet. Furthermore, hepatic levels of PGC-1α are reduced in 
mice fed a high saturated fat diet relative to mice fed a polyun-
saturated fat diet [58]. Because an inverse correlation between 
PGC-1α and tissue fat has been shown in other studies, we de-
termined the amount of PGC-1α present in the livers of wild-
type and PDK4
-/- mice [53]. As reported previously for liver and 
muscle of mice fed high saturated-fat diets [58,59], PGC-1α 
protein was reduced in the liver of wild-type mice fed the high 
saturated-fat diet compared to wild-type mice fed chow diet. 
In contrast, a normal amount of PGC-1α was present in the 
liver of PDK4
-/- mice fed the high saturated-fat diet [53]. Since 
PGC-1α controls expression of mitochondrial enzymes [56,57], 
these findings suggest that knocking out PDK4 creates condi-
tions that up regulate expression of PGC-1α and therefore genes 
that encode mitochondrial enzymes in the liver. This is a novel 
finding that may help explain why knocking out PDK4 reduc-
es fat accumulation in the liver of mice fed a high saturated-fat 
diet.
KNOCKING OUT PDK2 TOGETHER WITH 
PDK4 INDUCES GREATER EFFECTS ON 
BLOOD GLUCOSE LEVELS, GLUCOSE 
TOLERANCE, AND INSULIN SENSITIVITY 
THAN KNOCKING OUT ONLY PDK4 
PDK2/PDK4 double knockout (DKO) mice are viable and ap-
pear normal (N. H. Jeoung and R. A. Harris, unpublished stud-
ies). Blood glucose levels of the PDK2/PDK4 DKO mice are 
lower than that of wild-type mice in both the fed and the fast-
ed state. Overnight fasting induces lower blood levels of lactate, 
alanine, and pyruvate but higher blood levels of 3-hydroxybu-
tyrate and acetoacetate. Glucose tolerance is remarkably better 
in the PDK2/PDK4 DKO mice. Insulin levels remain lower dur-
ing the glucose tolerance test, suggesting the PDK2/PDK4 DKO 
mice are more sensitive to insulin.280
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SUMMARY AND PREDICTIONS
The schematic given in Fig. 4 summarizes how we visualize 
knocking out PDK4 affects blood glucose, FFAs, and ketone 
body levels. Less PDK activity results in greater PDC activity 
which reduces the levels of lactate, pyruvate, and alanine which 
attenuates hepatic glucose synthesis and results in lower blood 
glucose levels. Greater PDC activity results in production of 
excess acetyl-CoA which the liver converts to ketone bodies. 
Blood ketone bodies also increase because the increased oxi-
dation of pyruvate inhibits ketone body oxidation by periph-
eral tissues. It is likely that FFA oxidation is also inhibited in 
peripheral tissues, but FFAs levels are not greatly elevated, per-
haps because lipolysis in adipose tissue is inhibited by the ele-
vated concentrations of ketone bodies [60]. Although compli-
cated, insulin sensitivity may be increased because low PDC 
activity opposes the action of insulin. Greater PDC activity re-
sulting from reduced PDK activity may facilitate the action of 
insulin. 
  Knocking out PDK4 results in lower blood glucose levels, 
better glucose tolerance, and greater insulin sensitivity in chow 
fed mice. The same effects along with reduced hepatic steatosis 
are observed in PDK4
-/- mice fed a high saturated-fat diet. 
Knocking out both PDK2 and PDK4 lowers blood glucose 
more effectively and produces even better glucose tolerance 
and insulin sensitivity in chow fed mice. Based on these find-
ings, we predict that knocking out both PDK2 and PDK4 will 
have dramatic positive effects on blood glucose, glucose toler-
ance, and hepatic steatosis in mice fed a high saturated-fat 
diet. We also anticipate finding greater expression of PGC-1α, 
more mitochondria, and reduced levels of inflammatory 
markers in the liver of PDK2/PDK4 DKO mice. Such findings 
would provide further support for our contention that the PDKs 
may be good therapeutic targets for the treatment of type 2 di-
abetes. 
ACKNOWLEDGMENTS
This study was supported by funding from the WCU program 
through the National Research Foundation of Korea (N. H. J., 
R. A. H.) and a Merit Award from the Department of Veterans 
Affairs (R. A. H.) and by Basic Science Research Program 
through the National Research Foundation of Korea (NRF) 
funded by the Ministry of Education, Science and Technology 
(2010-0008815) (N. H. J.) 
 
REFERENCES
1. Harris RA, Popov KM, Zhao Y, Kedishvili NY, Shimomura Y, 
Crabb DW. A new family of protein kinases: the mitochondri-
al protein kinases. Adv Enzyme Regul 1995;35:147-62.
2 Patel MS, Korotchkina LG. Regulation of the pyruvate dehy-
drogenase complex. Biochem Soc Trans 2006;34(Pt 2):217-22.
3. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM. 
Evidence for existence of tissue-specific regulation of the mam-
malian pyruvate dehydrogenase complex. Biochem J 1998;329 
(Pt 1):191-6.
4. Huang B, Gudi R, Wu P, Harris RA, Hamilton J, Popov KM. 
Isoenzymes of pyruvate dehydrogenase phosphatase. DNA-
derived amino acid sequences, expression, and regulation. J 
Biol Chem 1998;273:17680-8.
5. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-
1 mediates adaptation to hypoxia by actively downregulating 
mitochondrial oxygen consumption. Cell Metab 2006;3:187-97. 
6. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-medi-
ated expression of pyruvate dehydrogenase kinase: a metabolic 
switch required for cellular adaptation to hypoxia. Cell Metab 
2006;3:177-85.
7. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate 
dehydrogenase kinase-3 by hypoxia-inducible factor-1 pro-
motes metabolic switch and drug resistance. J Biol Chem 2008; 
283:28106-14.
8. Wu P, Sato J, Zhao Y, Jaskiewicz J, Popov KM, Harris RA. Star-
Fig. 4.  Effect of inhibition of PDK4 on the metabolic control 
of carbohydrate and fat. KBs, ketone bodies; FFAs, free fatty 
acids; Glc, glucose; Lac, lactate; Pyr, pyruvate; CAC, citric acid 
cycle.
Glc Glc
Lac
Pyr
Acetyl-CoA
Lipolysis
Adipose
FFAs
KBs
PDC
PDK2/4
TCA
Acetyl-CoA
Pyr Lac281
Role of PDK4 in glucose metabolism
Korean Diabetes J 2010;34:274-283 www.e-kdj.org
vation and diabetes increase the amount of pyruvate dehydro-
genase kinase isoenzyme 4 in rat heart. Biochem J 1998;329(Pt 
1):197-201.
9. Wu P, Inskeep K, Bowker-Kinley MM, Popov KM, Harris RA. 
Mechanism responsible for inactivation of skeletal muscle py-
ruvate dehydrogenase complex in starvation and diabetes. Di-
abetes 1999;48:1593-9.
10. Wu P, Blair PV, Sato J, Jaskiewicz J, Popov KM, Harris RA. Star-
vation increases the amount of pyruvate dehydrogenase kinase 
in several mammalian tissues. Arch Biochem Biophys 2000;381: 
1-7.
11. Sugden MC, Kraus A, Harris RA, Holness MJ. Fibre-type spe-
cific modification of the activity and regulation of skeletal mus-
cle pyruvate dehydrogenase kinase (PDK) by prolonged star-
vation and refeeding is associated with targeted regulation of 
PDK isoenzyme 4 expression. Biochem J 2000;346 Pt 3:651-7.
12. Peters SJ, Harris RA, Heigenhauser GJ, Spriet LL. Muscle fiber 
type comparison of PDH kinase activity and isoform expression 
in fed and fasted rats. Am J Physiol Regul Integr Comp Physiol 
2001;280:R661-8.
13. Majer M, Popov KM, Harris RA, Bogardus C, Prochazka M. 
Insulin downregulates pyruvate dehydrogenase kinase (PDK) 
mRNA: potential mechanism contributing to increased lipid 
oxidation in insulin-resistant subjects. Mol Genet Metab 1998; 
65:181-6.
14. Huang B, Wu P, Bowker-Kinley MM, Harris RA. Regulation of 
pyruvate dehydrogenase kinase expression by peroxisome pro-
liferator-activated receptor-alpha ligands, glucocorticoids, and 
insulin. Diabetes 2002;51:276-83.
15. Abbot EL, McCormack JG, Reynet C, Hassall DG, Buchan KW, 
Yeaman SJ. Diverging regulation of pyruvate dehydrogenase 
kinase isoform gene expression in cultured human muscle cells. 
FEBS J 2005;272:3004-14.
16. Sugden MC, Bulmer K, Gibbons GF, Holness MJ. Role of peroxi-
some proliferator-activated receptor-alpha in the mechanism 
underlying changes in renal pyruvate dehydrogenase kinase 
isoform 4 protein expression in starvation and after refeeding. 
Arch Biochem Biophys 2001;395:246-52.
17. Burgess SC, Iizuka K, Jeoung NH, Harris RA, Kashiwaya Y, 
Veech RL, Kitazume T, Uyeda K. Carbohydrate-response ele-
ment-binding protein deletion alters substrate utilization pro-
ducing an energy-deficient liver. J Biol Chem 2008;283:1670-8.
18. Ravindran S, Radke GA, Guest JR, Roche TE. Lipoyl domain-
based mechanism for the integrated feedback control of the 
pyruvate dehydrogenase complex by enhancement of pyruvate 
dehydrogenase kinase activity. J Biol Chem 1996;271:653-62. 
19. Baker JC, Yan X, Peng T, Kasten S, Roche TE. Marked differ-
ences between two isoforms of human pyruvate dehydroge-
nase kinase. J Biol Chem 2000;275:15773-81.
20. Behal RH, Buxton DB, Robertson JG, Olson MS. Regulation of 
the pyruvate dehydrogenase multienzyme complex. Annu Rev 
Nutr 1993;13:497-520.
21. Holness MJ, Kraus A, Harris RA, Sugden MC. Targeted upreg-
ulation of pyruvate dehydrogenase kinase (PDK)-4 in slow-
twitch skeletal muscle underlies the stable modification of the 
regulatory characteristics of PDK induced by high-fat feeding. 
Diabetes 2000;49:775-81.
22. Rosa G, Di Rocco P, Manco M, Greco AV, Castagneto M, Vidal 
H, Mingrone G. Reduced PDK4 expression associates with in-
creased insulin sensitivity in postobese patients. Obes Res 2003; 
11:176-82.
23. Spriet LL, Tunstall RJ, Watt MJ, Mehan KA, Hargreaves M, 
Cameron-Smith D. Pyruvate dehydrogenase activation and 
kinase expression in human skeletal muscle during fasting. J 
Appl Physiol 2004;96:2082-7.
24. Bajotto G, Murakami T, Nagasaki M, Tamura T, Tamura N, 
Harris RA, Shimomura Y, Sato Y. Downregulation of the skel-
etal muscle pyruvate dehydrogenase complex in the Otsuka 
Long-Evans Tokushima Fatty rat both before and after the on-
set of diabetes mellitus. Life Sci 2004;75:2117-30.
25. Chokkalingam K, Jewell K, Norton L, Littlewood J, van Loon 
LJ, Mansell P, Macdonald IA, Tsintzas K. High-fat/low-carbo-
hydrate diet reduces insulin-stimulated carbohydrate oxida-
tion but stimulates nonoxidative glucose disposal in humans: 
An important role for skeletal muscle pyruvate dehydrogenase 
kinase 4. J Clin Endocrinol Metab 2007;92:284-92. 
26. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabe-
tes. J Clin Invest 2005;115:1111-9.
27. Watt MJ, Hevener AL. Fluxing the mitochondria to insulin re-
sistance. Cell Metab 2008;7:5-6.
28. Jeoung NH, Wu P, Joshi MA, Jaskiewicz J, Bock CB, Depaoli-
Roach AA, Harris RA. Role of pyruvate dehydrogenase kinase 
isoenzyme 4 (PDHK4) in glucose homoeostasis during starva-
tion. Biochem J 2006;397:417-25.
29. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, 
Zhang XM, Cline GW, Yu XX, Geisler JG, Bhanot S, Monia BP, 
Shulman GI. Reversal of diet-induced hepatic steatosis and 
hepatic insulin resistance by antisense oligonucleotide inhibi-
tors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 2006;116: 
817-24. 282
Jeoung NH, et al.
Korean Diabetes J 2010;34:274-283 www.e-kdj.org
30. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkaye-
va O, Bain J, Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, 
Muoio DM. Mitochondrial overload and incomplete fatty acid 
oxidation contribute to skeletal muscle insulin resistance. Cell 
Metab 2008;7:45-56.
31. Jeoung NH, Harris RA. Pyruvate dehydrogenase kinase-4 defi-
ciency lowers blood glucose and improves glucose tolerance in 
diet-induced obese mice. Am J Physiol Endocrinol Metab 
2008;295:E46-54. 
32. Stacpoole PW. The pharmacology of dichloroacetate. Metabo-
lism 1989;38:1124-44.
33. Crabb DW, Yount EA, Harris RA. The metabolic effects of di-
chloroacetate. Metabolism 1981;30:1024-39.
34. Clark AS, Mitch WE, Goodman MN, Fagan JM, Goheer MA, 
Curnow RT. Dichloroacetate inhibits glycolysis and augments 
insulin-stimulated glycogen synthesis in rat muscle. J Clin In-
vest 1987;79:588-94.
35. Yount EA, Felten SY, O’Connor BL, Peterson RG, Powell RS, 
Yum MN, Harris RA. Comparison of the metabolic and toxic 
effects of 2-chloropropionate and dichloroacetate. J Pharmacol 
Exp Ther 1982;222:501-8.
36. Korotchkina LG, Sidhu S, Patel MS. R-lipoic acid inhibits mam-
malian pyruvate dehydrogenase kinase. Free Radic Res 2004;38: 
1083-92.
37. Walgren JL, Amani Z, McMillan JM, Locher M, Buse MG. Ef-
fect of R(+)alpha-lipoic acid on pyruvate metabolism and fatty 
acid oxidation in rat hepatocytes. Metabolism 2004;53:165-73.
38. Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, 
Augustin HJ, Dietze GJ, Rett K. Oral administration of RAC-al-
pha-lipoic acid modulates insulin sensitivity in patients with 
type-2 diabetes mellitus: a placebo-controlled pilot trial. Free 
Radic Biol Med 1999;27:309-14.
39. Konrad T, Vicini P, Kusterer K, Hoflich A, Assadkhani A, Bohles 
HJ, Sewell A, Tritschler HJ, Cobelli C, Usadel KH. Alpha-Lipo-
ic acid treatment decreases serum lactate and pyruvate con-
centrations and improves glucose effectiveness in lean and obese 
patients with type 2 diabetes. Diabetes Care 1999;22:280-7.
40. Blumenthal SA. Inhibition of gluconeogenesis in rat liver by li-
poic acid. Evidence for more than one site of action. Biochem J 
1984;219:773-80.
41. Lee WJ, Lee IK, Kim HS, Kim YM, Koh EH, Won JC, Han SM, 
Kim MS, Jo I, Oh GT, Park IS, Youn JH, Park SW, Lee KU, Park 
JY. Alpha-lipoic acid prevents endothelial dysfunction in obese 
rats via activation of AMP-activated protein kinase. Arterio-
scler Thromb Vasc Biol 2005;25:2488-94.
42. Bebernitz GR, Aicher TD, Stanton JL, Gao J, Shetty SS, Knorr 
DC, Strohschein RJ, Tan J, Brand LJ, Liu C, Wang WH, Vinlu-
an CC, Kaplan EL, Dragland CJ, DelGrande D, Islam A, Lozito 
RJ, Liu X, Maniara WM, Mann WR. Anilides of (R)-trifluoro-
2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate 
dehydrogenase kinase. J Med Chem 2000;43:2248-57.
43. Morrell JA, Orme J, Butlin RJ, Roche TE, Mayers RM, Kilgour 
E. AZD7545 is a selective inhibitor of pyruvate dehydrogenase 
kinase 2. Biochem Soc Trans 2003;31(Pt 6):1168-70.
44. Kato M, Li J, Chuang JL, Chuang DT. Distinct structural mech-
anisms for inhibition of pyruvate dehydrogenase kinase iso-
forms by AZD7545, dichloroacetate, and radicicol. Structure 
2007;15:992-1004.
45. Mayers RM, Leighton B, Kilgour E. PDH kinase inhibitors: a 
novel therapy for Type II diabetes? Biochem Soc Trans 2005;33 
(Pt 2):367-70. 
46. Aicher TD, Damon RE, Koletar J, Vinluan CC, Brand LJ, Gao J, 
Shetty SS, Kaplan EL, Mann WR. Triterpene and diterpene in-
hibitors of pyruvate dehydrogenase kinase (PDK). Bioorg Med 
Chem Lett 1999;9:2223-8.
47. Cadoudal T, Distel E, Durant S, Fouque F, Blouin JM, Collinet 
M, Bortoli S, Forest C, Benelli C. Pyruvate dehydrogenase ki-
nase 4: regulation by thiazolidinediones and implication in 
glyceroneogenesis in adipose tissue. Diabetes 2008;57:2272-9.
48. Reshef L, Olswang Y, Cassuto H, Blum B, Croniger CM, Kalhan 
SC, Tilghman SM, Hanson RW. Glyceroneogenesis and the tri-
glyceride/fatty acid cycle. J Biol Chem 2003;278:30413-6.
49. Olswang Y, Cohen H, Papo O, Cassuto H, Croniger CM, Haki-
mi P, Tilghman SM, Hanson RW, Reshef L. A mutation in the 
peroxisome proliferator-activated receptor gamma-binding 
site in the gene for the cytosolic form of phosphoenolpyruvate 
carboxykinase reduces adipose tissue size and fat content in 
mice. Proc Natl Acad Sci U S A 2002;99:625-30. 
50. Franckhauser S, Munoz S, Elias I, Ferre T, Bosch F. Adipose 
overexpression of phosphoenolpyruvate carboxykinase leads 
to high susceptibility to diet-induced insulin resistance and 
obesity. Diabetes 2006;55:273-80.
51. Hakimi P, Yang J, Casadesus G, Massillon D, Tolentino-Silva F, 
Nye CK, Cabrera ME, Hagen DR, Utter CB, Baghdy Y, Johnson 
DH, Wilson DL, Kirwan JP, Kalhan SC, Hanson RW. Overex-
pression of the cytosolic form of phosphoenolpyruvate car-
boxykinase (GTP) in skeletal muscle repatterns energy metab-
olism in the mouse. J Biol Chem 2007;282:32844-55.
52. Kalhan SC, Bugianesi E, McCullough AJ, Hanson RW, Kelley 
DE. Estimates of hepatic glyceroneogenesis in type 2 diabetes 283
Role of PDK4 in glucose metabolism
Korean Diabetes J 2010;34:274-283 www.e-kdj.org
mellitus in humans. Metabolism 2008;57:305-12.
53. Hwang B, Jeoung NH, Harris RA. Pyruvate dehydrogenase ki-
nase isoenzyme 4 (PDHK4) deficiency attenuates the long-term 
negative effects of a high-saturated fat diet. Biochem J 2009;423: 
243-52.
54. Rossmeisl M, Rim JS, Koza RA, Kozak LP. Variation in type 2 
diabetes--related traits in mouse strains susceptible to diet-in-
duced obesity. Diabetes 2003;52:1958-66. 
55. Vendemiale G, Grattagliano I, Caraceni P, Caraccio G, Do-
menicali M, Dall’Agata M, Trevisani F, Guerrieri F, Bernardi 
M, Altomare E. Mitochondrial oxidative injury and energy 
metabolism alteration in rat fatty liver: effect of the nutritional 
status. Hepatology 2001;33:808-15.
56. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Moo-
tha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. 
Mechanisms controlling mitochondrial biogenesis and respi-
ration through the thermogenic coactivator PGC-1. Cell 1999; 
98:115-24.
57. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, 
Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-
Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, 
Saffitz JE, Abel ED, Semenkovich CF, Kelly DP. PGC-1alpha de-
ficiency causes multi-system energy metabolic derangements: 
muscle dysfunction, abnormal weight control and hepatic ste-
atosis. PLoS Biol 2005;3:e101.
58. You M, Considine RV, Leone TC, Kelly DP, Crabb DW. Role of 
adiponectin in the protective action of dietary saturated fat 
against alcoholic fatty liver in mice. Hepatology 2005;42:568-77. 
59. Crunkhorn S, Dearie F, Mantzoros C, Gami H, da Silva WS, 
Espinoza D, Faucette R, Barry K, Bianco AC, Patti ME. Peroxi-
some proliferator activator receptor gamma coactivator-1 ex-
pression is reduced in obesity: potential pathogenic role of sat-
urated fatty acids and p38 mitogen-activated protein kinase 
activation. J Biol Chem 2007;282:15439-50. 
60. Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, Ippolito M, Ren 
N, Kaplan R, Wu K, Wu TJ, Jin L, Liaw C, Chen R, Richman J, 
Connolly D, Offermanns S, Wright SD, Waters MG. (D)-beta-
Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic 
acid receptor PUMA-G. J Biol Chem 2005;280:26649-52. 